Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from CLDX

2 ‘Strong Buy’ Growth Stocks With Upside of Around 200%

These growth stocks have the potential to dramatically outperform if you are willing to bear the risks.

Barchart · Jan 27

Celldex Therapeutics Pulls Plug On Eosinophilic Esophagitis Investigational Drug As Data Falls Short

On Tuesday, Celldex Therapeutics, Inc. (NASDAQ:CLDX) released topline results from its ongoing Phase 2 study of barzolvolimab in eosinophilic esophagitis (EoE), a chronic inflammatory disease of the esophagus.

Benzinga · Aug 20, 2025

Can This Growth Stock Deliver 135% Upside in 2025?

Positive clinical trial results have sparked hope for this biotech.

Barchart · Oct 22, 2024

From analysis to the latest developments in health,
read the most diverse news in one place.

Read How Cantor Views Celldex Therapeutics' Barzolvolimab Data

Celldex Therapeutics Inc's (NASDAQ:CLDX) shares closed almost 16% down on Friday after releasing Phase 1b study data of barzolvolimab. Cantor says the main reason for stock being down is the four patient adverse events on the generally transient, asymptomatic, and mild neutrophil decreases, noting a single Grade 3 case. One patient had values…

Benzinga · Jul 5, 2022

Celldex's Barzolvolimab Shows Rapid, Durable Responses In Early Urticaria Study

Celldex Therapeutics Inc (NASDAQ:CLDX) announced interim data from Phase 1b trial of barzolvolimab in chronic spontaneous urticaria (CSU) refractory to antihistamines. CSU is characterized by the occurrence of hives or weals for six weeks or longer without identifiable specific triggers or causes. Data show that multiple doses of barzolvolimab resulted in dose-dependent decreases…

Benzinga · Jul 1, 2022

Celldex Therapeutics: Q4 Earnings Insights

Celldex Therapeutics (NASDAQ:CLDX) reported its Q4 earnings results on Monday, February 28, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Benzinga · Feb 28, 2022

Coverage From

People

Thomas Smith

36 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.